
Claims

1. A solid dispersion comprising  (ARN-509), a poly(meth)acrylate copolymer and hydroxypropyl methylcellulose acetate succinate (HPMCAS).

2. The solid dispersion according to claim 1 wherein the dispersion consists of ARN-509, a poly(meth)acrylate copolymer and HPMCAS.

3. The solid dispersion according to claim 1 or 2 wherein the weight-by-weight ratio of ARN-509 : (poly(meth)acrylate copolymer and HPMCAS) in the solid dispersion is in the range from 1 : 1 to 1 : 5.

4. The solid dispersion according to claim 3 wherein the weight-by-weight ratio of ARN-509 : (poly(meth)acrylate copolymer and HPMCAS) in the solid dispersion is 1:3.

5. The solid dispersion according to claim 3 wherein the weight-by-weight ratio of ARN-509 : (poly(meth)acrylate copolymer and HPMCAS) in the solid dispersion is 1:2.

6. The solid dispersion according to claim 3 wherein the weight-by-weight ratio of ARN-509 : (poly(meth)acrylate copolymer and HPMCAS) in the solid dispersion is 1:1.

7. The solid dispersion according to any one of the preceding claims wherein the weight-by-weight ratio of poly(meth)acrylate copolymer to HPMCAS in the solid dispersion ranges from 5:95 to 95:5.

8. The solid dispersion according to claim 7 wherein the weight-by-weight ratio of poly(meth)acrylate copolymer to HPMCAS in the solid dispersion ranges from 25:75 to 75:25.

9. The solid dispersion according to claim 8 wherein the weight-by-weight ratio of poly(meth)acrylate copolymer to HPMCAS in the solid dispersion is 50:50.

10. The solid dispersion according to any one of the preceding claims wherein ARN-509 is present in amorphous form.

11. The solid dispersion according to any one of the preceding claims wherein the dispersion is a solid solution.

12. The solid dispersion according to any one of the preceding claims wherein the poly(meth)acrylate copolymer is poly(methacrylic acid-co-ethyl acrylate) 1:1.

13. The solid dispersion according to any one of the preceding claims wherein the HPMCAS is HPMCAS granular grade.

14. The solid dispersion according to any one of the preceding claims obtainable by spray drying.

15. The solid dispersion according to any one of claims 1 to 13 obtainable by hot melt extrusion.

16. A particle consisting of a solid dispersion as defined in any one of the preceding claims.

17. A particle comprising a solid dispersion as defined in any one of claims 1 to 15.

18. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a solid dispersion according to any one of claims 1 to 15.

19. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a particle according to claim 16 or 17.

20. The formulation according to claim 18 or 19 wherein the formulation comprises 60 mg of ARN-509.

21. The formulation according to claim 18 or 19 wherein the formulation comprises 120 mg of ARN-509.

22. The formulation according to claim 18 or 19 wherein the formulation comprises 240 mg of ARN-509.

23. The formulation according to any one of claims 18 to 22 wherein the weight of the solid dispersion ranges from 20 to 40 % of the total weight of the formulation.

24. The formulation according to any one of claims 18 to 23 wherein the formulation is a tablet.

25. The formulation according to claim 24 which is suitable for oral administration.

26. A process for preparing the solid dispersion according to claim 14 comprising the steps of mixing ARN-509, a poly(meth)acrylate copolymer and HPMCAS in a suitable solvent and spray drying said mixture.

27. The process according to claim 26 wherein the suitable solvent is a mixture of dichloromethane and methanol.

28. The process according to claim 27 wherein the weight:weight ratio of dichloromethane to methanol in the mixture is 50:50.

29. Use of the pharmaceutical formulation according to any one of claims 18 to 25 for the preparation of a medicament for the treatment of prostate cancer.

30. Use according to claim 29 wherein the medicament is for oral administration.

31. A combination of a pharmaceutical formulation according to any one of claims 18 to 25 and another anticancer agent.

32. The combination according to claim 31 wherein the other anticancer agent is an androgen biosynthesis inhibitor.

33. The combination according to claim 31 wherein the other anticancer agent is abiraterone acetate.

34. The combination according to any one of claims 31 to 33 further comprising prednisone.